Zacks Investment Research | Feb 03, 2019 08:58PM ET
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is likely to beat expectations when it releases fourth-quarter and full year 2018 results on Feb 6, before the opening bell.
In the last reported quarter, Regeneron beat earnings expectations by 12.7%. The company’s track record is excellent. In the last four quarters, it surpassed earnings estimates on all occasions, with average beat of 10.9%. Let’s see how things are shaping up for the to-be-reported quarter.
Why a Likely Positive Surprise?
Our proven model indicates that Regeneron is likely to beat earnings estimates this quarter because it has the right combination of two key ingredients — a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold).
Earnings ESP: The Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, is +6.8%. This is because the Most Accurate Estimate is $6.08, while the Zacks Consensus Estimate is $5.69. You can uncover the best stocks to buy or sell, before they’re reported, with our industry ’s decline of 12.5%.
Other Stocks That Warrant a Look
Here are a couple of health care stocks you may want to consider as our model shows that these too have the right combination of elements to post an earnings beat this quarter.
Seattle Genetics (NASDAQ:SGEN) has an Earnings ESP of +12.82% and a Zacks Rank #2. The company is scheduled to report results on Feb 7. You can see Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.